NCT05309200已完成2 期
A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Adaptive Dose-Ranging Study to Assess Safety and Efficacy of Intravenous OCE-205 in Adults Diagnosed With Cirrhosis With Ascites Who Have Developed Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 47
- 试验地点
- 23
- 主要终点
- Time to measurement of concentration serum creatinine (sCr) value of less than 1.5 mg/dL on 2 consecutive days
研究概览
简要总结
OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites.
The study aims are to evaluate the safety and efficacy of OCE-205 at various doses.
Participants will receive treatment by intravenous infusion. Participants will continue with this treatment until participants meets primary endpoint or any discontinuation criteria.
详细描述
The study will include 5 treatment arms including 1 Placebo Arm and 4 active drug arms. Participants will be randomly selected to 1 of 5 arms.
- Placebo
- OCE-205 at 8 micrograms per hour (µg/hr)
- OCE-205 at 15 micrograms per hour (µg/hr)
- OCE-205 at 30 micrograms per hour (µg/hr)
- OCE-205 at 50 micrograms per hour (µg/hr)
This multi-center trial will be conducted in the United States and Canada. If selected for the study, participants will be randomly assigned to 1 of the 5 treatment arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form (ICF) by participant or their legal/authorized representatives.
- •Diagnosed with decompensated cirrhosis with ascites.
- •Receiving albumin and has had appropriate diuretic withdrawal for at least 2 days prior to randomization into the study.
- •Beta-blockers should be discontinued 48 hours prior to randomization, unless doctor deems necessary for appropriate medical treatment.
- •No sustained improvement in renal function after both diuretic withdrawal and plasma volume expansion with albumin.
- •Female participants must have a negative pregnancy test prior to randomization and agree to avoid becoming pregnant during the study and for 30 days after the end of treatment. Male participants must agree to use 2 effective contraceptive methods during the study and up to 30 days after the end of treatment.
排除标准
- •Serum Creatinine >3.8 mg/dL.
- •Large volume paracentesis (LVP ≥6L) within 4 days of randomization.
- •Pulse oximeter reading of <90% on 2L or less.
- •Sepsis and/or uncontrolled bacterial infection.
- •Experienced shock within 72 hrs prior to screening.
- •Model for End-Stage Liver Disease (MELD) score >
- •Hypertension with a Systolic BP > 140 mmHg and/ or a Diastolic BP >100 mmHg.
- •Treated with or exposed to nephrotoxic agents or has had exposure to radiographic contrast agents within 72 hrs prior to screening.
- •Has superimposed acute liver injury due to drugs, or toxins except for acute alcoholic hepatitis.
- •Proteinuria greater than 500 mg/dL.
- •Impaired cardiac function as evidenced by symptoms consistent with New York Heart Association Classification Class 2 or worse.
- •Received Renal Replacement Therapy (RRT) within 4 weeks of randomization.
- •Has had a Trans Jugular Intrahepatic Porto-systemic shunt (TIPS).
- •Pregnant or breastfeeding.
- •Diagnosed with a malignancy within the past 5 years.
- •History or current evidence of any condition (COVID-19 positive with respiratory/cardiac complications), therapy or laboratory abnormality that might confound the results of the study, interfere with the participation for the full duration of the study, or is not in the best interest to participate in the opinion of the investigator.
- •Participated in a study of an investigational medical product or device within the last 8 weeks preceding screening.
- •Experienced a major blood loss (≥500 mL) within the last 4 weeks prior to screening.
- •Is stuporous or comatose at screening (West Haven scores III and IV). exhibiting bradycardia.
研究组 & 干预措施
OCE-205 Cohort 4
Experimental
OCE-205, 30 µg/hr, intravenous infusion
干预措施: OCE-205 (Drug)
OCE-205 Cohort 1
Placebo Comparator
Placebo, intravenous infusion
干预措施: Placebo (Drug)
OCE-205 Cohort 2
Experimental
OCE-205, 8 µg/hr, intravenous infusion
干预措施: OCE-205 (Drug)
OCE-205 Cohort 3
Experimental
OCE-205, 15 µg/hr, intravenous infusion
干预措施: OCE-205 (Drug)
OCE-205 Cohort 5
Experimental
OCE-205, 50 µg/hr, intravenous infusion
干预措施: OCE-205 (Drug)
结局指标
主要结局
Time to measurement of concentration serum creatinine (sCr) value of less than 1.5 mg/dL on 2 consecutive days
时间窗: From Day 1 infusion start to Last Day of infusion end
次要结局
- Change in concentration of Serum Creatinine (sCr)(From Day 1 infusion start to Last Day of infusion end)
- Change in Pulse Rate(From Day 1 infusion start to Last Day of infusion end)
- Volume of Steady-State Volume of Distribution (Vss) of OCE-205(From Day 1 infusion start to Last Day of infusion end)
- Change in Mean Arterial Pressure (MAP) rate(From Day 1 infusion start to Last Day of infusion end)
- Percentage Change in rate of Mean Arterial Pressure (MAP)(From Day 1 infusion start to Last Day of infusion end)
- Percentage Change in Pulse Rate(From Day 1 infusion start to Last Day of infusion end)
- Mean Concentration of OCE-205 at Steady State Concentration (Css)(From Day 1 infusion start to Last Day of infusion end)
- Rate of Total Body Clearance (CL) of OCE-205(From Day 1 infusion start to Last Day of infusion end)
- Time to Elimination Half-Life (t1/2) of OCE-205(From Day 1 infusion start to Last Day of infusion end)
研究者
研究点 (23)
Loading locations...
相似试验
已完成
不适用
Randomised, controlled multicentre-trial for the optimised therapy of the acutely ischaemic limb with controlled reperfusioAcutely ischaemic limbCirculatory SystemISRCTN29807122niversity Hospital Freiburg (Germany)174
尚未招募
2 期
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRCCRCNCT05239650Shanghai Henlius Biotech50
招募中
3 期
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)H3 K27MGliomaNCT05580562Jazz Pharmaceuticals510
已完成
2 期
A Study of Quintuple Therapy to Treat COVID-19 InfectionCOVID-19Corona Virus InfectionCoronavirus-19Sars-CoV2NCT04334512ProgenaBiome118
已完成
1 期
The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult SubjectsNonalcoholic Steatohepatitis (NASH)NCT04194242Sunshine Lake Pharma Co., Ltd.64